Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, NUVL, EWTX, GMAB, SYRE, and represent 56.92% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: SYRE (+$167M), ALNY (+$145M), GMAB (+$142M), MBX (+$138M), EWTX (+$116M), NUVL (+$74M), TNGX (+$73M), VRDN (+$66M), JBIO (+$64M), ACHV (+$32M).
- Started 7 new stock positions in MPLT, EDIT, MBX, JBIO, ACHV, ALNY, Kardigan Ord.
- Reduced shares in these 10 stocks: ACLX (-$663M), PCVX (-$155M), Centessa Pharmaceuticals (-$142M), TERN (-$117M), CYTK (-$98M), ABVX (-$86M), MAZE (-$82M), SRRK (-$60M), MIRM (-$58M), RVMD (-$55M).
- Sold out of its positions in ABVX, ACLX, BBOT, Centessa Pharmaceuticals, CYTK, KLRS, MAZE, MIRM, ORIC, SRRK. GPCR, TERN, MANE, URGN.
- Paradigm Biocapital Advisors was a net seller of stock by $-508M.
- Paradigm Biocapital Advisors has $5.3B in assets under management (AUM), dropping by 9.12%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 28 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 22.3 | $1.2B | -4% | 6.4M | 187.28 |
|
| Nuvalent Inc-a (NUVL) | 13.7 | $732M | +11% | 5.9M | 123.50 |
|
| Edgewise Therapeutics (EWTX) | 7.8 | $415M | +38% | 10M | 40.63 |
|
| Genmab A/s Sponsored Ads (GMAB) | 6.8 | $361M | +64% | 13M | 27.47 |
|
| Spyre Therapeutics Com New (SYRE) | 6.4 | $341M | +96% | 3.8M | 88.78 |
|
| Apogee Therapeutics (APGE) | 3.9 | $209M | +16% | 1.6M | 132.73 |
|
| Oruka Therapeutics (ORKA) | 3.8 | $204M | -7% | 2.1M | 95.17 |
|
| Tango Therapeutics (TNGX) | 3.7 | $199M | +58% | 6.4M | 31.26 |
|
| Belite Bio Sponsored Ads (BLTE) | 3.6 | $190M | +10% | 1.2M | 153.99 |
|
| Erasca (ERAS) | 3.3 | $175M | -8% | 9.6M | 18.32 |
|
| Tarsus Pharmaceuticals (TARS) | 3.3 | $175M | +8% | 2.8M | 62.94 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.7 | $145M | NEW | 480k | 301.03 |
|
| Insmed Com Par $.01 (INSM) | 2.6 | $141M | +5% | 1.3M | 106.62 |
|
| Mbx Biosciences (MBX) | 2.6 | $138M | NEW | 2.5M | 55.20 |
|
| Vaxcyte (PCVX) | 2.3 | $124M | -55% | 2.1M | 58.13 |
|
| Miragen Therapeutics (VRDN) | 2.3 | $124M | +113% | 6.7M | 18.37 |
|
| Olema Pharmaceuticals (OLMA) | 2.0 | $109M | +8% | 8.7M | 12.51 |
|
| Jade Biosciences Com New (JBIO) | 1.2 | $64M | NEW | 2.9M | 22.22 |
|
| Tyra Biosciences (TYRA) | 1.1 | $58M | -11% | 1.8M | 31.94 |
|
| Assembly Biosciences Com New (ASMB) | 0.8 | $43M | +133% | 1.6M | 27.48 |
|
| Eyepoint Com New (EYPT) | 0.8 | $41M | -8% | 2.9M | 14.30 |
|
| Achieve Life Sciences (ACHV) | 0.6 | $32M | NEW | 5.0M | 6.53 |
|
| Vor Biopharma Com New (VOR) | 0.6 | $32M | 1.8M | 18.41 |
|
|
| Maplight Therapeutics (MPLT) | 0.5 | $25M | NEW | 686k | 35.84 |
|
| Kardigan Ord | 0.4 | $22M | NEW | 900k | 23.85 |
|
| Lexeo Therapeutics (LXEO) | 0.4 | $19M | -32% | 4.2M | 4.66 |
|
| Editas Medicine (EDIT) | 0.3 | $18M | NEW | 5.6M | 3.24 |
|
| Inventiva Sa Ads (IVA) | 0.3 | $15M | 4.0M | 3.78 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2026 Q2 filed Aug. 14, 2026
- Paradigm Biocapital Advisors 2026 Q1 filed May 15, 2026
- Paradigm Biocapital Advisors 2025 Q4 filed Feb. 17, 2026
- Paradigm Biocapital Advisors 2025 Q3 filed Nov. 14, 2025
- Paradigm Biocapital Advisors 2025 Q2 filed Aug. 14, 2025
- Paradigm Biocapital Advisors 2025 Q1 filed May 15, 2025
- Paradigm Biocapital Advisors 2024 Q4 filed Feb. 14, 2025
- Paradigm Biocapital Advisors 2024 Q3 filed Nov. 14, 2024
- Paradigm Biocapital Advisors 2024 Q2 filed Aug. 14, 2024
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022